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1. ABSTRACT
Previous  study  shows  (or)  reveals  that  ascorbic  acid  addition  to  plasma  can
prevent the decomposition of the rifampicin. The present study was aimed to investigate
the influence of ascorbic acid in different concentrations on the stability and also on the
pharmacokinetics  of  rifampicin  in  rabbits  at  pH1.2  medium. Rifampicin  alone  and  in
combination with isoniazid in the presence of ascorbic acid in different ratios (125mg,
250mg,500mg)  were  used  for  this  study.  Percent  degradation  of  rifampicin  was
significantly reduced by addition of ascorbic acid in pH 1.2 medium and the effect was
found to be dependent up on the concentration of ascorbic acid. The study was extended
in animal model and it was observed that all pharmacokinetic parameters such as  ka, ke,
vd t1/2, Cmax, Tmax, AUC (0-12), AUC of rifampicin was significantly influenced by ascorbic
acid as compared to that of rifampicin alone and in combination with isoniazid Ka, ke,vd,
Cmax,  AUC(0-12) and AUC (0-∞) were increased with increase in ascorbic acid concentration;
however, Tmax, T1/2 of rifampicin was shown decreased with increase in ascorbic acid
concentration.  The  results  conclusively  shows  that  in  presence  of  isoniazid   the
absorption of rifampicin was decreased, where as ascorbic acid addition to rifampicin can
improve the bioavailability of rifampicin.
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2. INTRODUCTION
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis.
It  is  the  world’s  second  commonest  cause  of  death  from  infectious  disease  after
HIV/AIDS;  approximately  one  third  of  the  world  population  is  suffering  with  this
disease.  TB has  been declared a public  health  emergency by the WORLD HEALTH
ORGANIZATION (WHO). A control programmed reaches the WHO targets of 70% case
detection  and  85%  cure.  Without  greater  effort  to  control  tuberculosis,  the  annual
incidence of the disease is expected to increase by 41% (21-61) between 1998 and 2020
(from  7.4million  to  10.6  million  cases  per  year).Achievement  of  WHO  targets  by
2010would prevent 23% (15-30) or 48 million cases by 2020.1
The anti-TB drugs have been categorized into two types. Namely, first line and
second  line  drugs.  First  line  drugs  are  Rifampicin  (RIF)  and  Isoniazid  (INH),
Pyrazinamide  (PYZ),  Ethamabutol  (ETB)  and  Streptomycin.  Second  line  drugs  are
Capreomycin,  Anamycin,  Ethionamide,  Para  -amino  salicylic  acid,  Cyclosporine,
Thiacetazone, Ciprofloxacin, Ofloxacin and Sparfloxacin.2
INH eradicates most of the rapidly replicating bacilli in the first 2 weeks of the
treatment,  together  with  streptomycin  and  ETB.  Thereafter,  RIF  and  PYZ  have  an
important role in the sterilization of lesions by eradicating organisms. These two drugs
are crucial for successful 6-month treatment. RIF kills non-replicating organisms and the
high sterilizing effect of PYZ serves to act on semi dormant bacilli not affected by any
other anti-TB drugs3, INH and RIF, these two are most potent TB drugs, kills more than
99% of the tubercular bacilli within 2 months initiation therapy.4
Rifampicin is a semi synthetic derivative isolated from streptomyces mediterranei5 and is
highly effective on short term course of anti tuberculosis regimens and has an important
role in killing the semi dormant tubercle bacilli. Rifampicin is bactericidal and acts on
both intra and extra- cellular organisms. Rifampicin acts by inhibiting the bacterial DNA-
dependent  RNA  polymerase,  thus  stopping  the  expression  of  bacterial  genes.
Hepatotoxicity due to Rifampicin has been reported.6
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Rifampicin,  Isoniazid,  Pyrazinamide,  Ethambutol  were  earlier  prescribed  as  a
separate  formulation in  TB treatment.  To  increase  the  patient  compliance,  the  World
Health Organization (WHO) and the International Union Against Tuberculosis and Lung
Disease  (IUATID)  encourage  the  use  of  fixed  dose  combinations  (FDC)  tablets  that
ensures ingestion of all the components therapy. By facilitating the delivery of correct
drug doses, FDC are expected to reduce the risk of emergency of drug resistant TB.
After oral administration of Rifampicin on empty stomach, the absorption is rapid
with a single 600mg dose peak level  is achieved within 2-3hours after administration
.Food  interferes  with  its  absorption7.  Almost  85% of  the  drug  gets  bound  to  serum
proteins and it is metabolized in the liver to an active metabolite, deacetylrifampin and
undergoes enterohepatic recycling. A mean RIF maximal serum concentration (Cmax) of
10.54±  3.18µg/ml  the  time  which  it  is  occurred  (Tmax)  OF  2.42±1.32hrs,  and  the
(AUC0-∞) of 57.15±13.41µg.h.ml on fasting conditions.8 The previous study indicates
that  Rifampicin  alone  was  degrade  by  12.4%  in  acidic  medium  in  1hr  to  3-
formylrifampicin and in the presence of Isoniazid the degradation is increased to 21.5%
and also indicated that the degradation of Rifampicin to 3-formylrifampicin is  almost
more than the two times faster in the presence of Isoniazid than that of the Rifampicin
alone.9
Though  FDC  of  RIF,  INH,  PYZ,ETB   is  advocated  to  combat  multi  drug
resistance TB induced by separate formulations of these drugs, degradation of Rifampicin
by the  influence  of  Isoniazid  resulting  poor  bioavailability  of  Rifampicin  is  a  major
concern for effective control of TB. Rifampicin is primarily absorbed from the stomach
where  as  INH  absorbed  from  intestine.  Therefore  formulations  were  developed  that
release RIF in the stomach and INH in the intestine to prevent degradation of Rifampicin
by the Isoniazid in the stomach.
Earlier study shows that ascorbic acid administration prevents the degradation of
RIF. Another study reports that RIF oxides in solution to form rifampicin quinone and the
addition of ascorbic acid slow down this oxidation .10Use of rifampicin (1000mg/day) is
also recommended in tuberculosis patients.11
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Thus RIF appears the best choice for TB, however, its poor bioavailability from
FDC due to degradation in the stomach in the presence or absence of INH following oral
administration   still remains a concern for effective management of TB associated with
bacterial  resistance.  Hence  development  of  any  method  that  would  standardize  RIF
against degradation in the stomach will be therapeutically beneficial. So in the present
study an attempt was made to investigate the influence of ascorbic acid, an antioxidant
and improving the  pharmacokinetics  of  rifampicin  following oral  administration.  The
outcome  of  the  study  may  provide  an  in-sight  into  adjusting  the  dose  regimen  of
rifampicin with improved bioavailability for effective management of tuberculosis.
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LITERATURE
3.  REVIEW OF LITERATURE
Tuberculosis  is  believed  to  claim  2  million  lives  a  year  all  over  the  world.
Countries with poor healthcare systems suffer most. Emergency of multi drug resistant
(MDR) strains of M. tuberculosis and a co-infection with AIDS prompted WHO in March
1993 to declare tuberculosis as Global Health Emergency (Annon, 1997).
Rifampicin (RIF),  Isoniazid (INH), Pyrazinamide (PZ),  and Ethambutol  (ETB)
are the drugs of choice for treating tuberculosis. Fixed Dose Combinations (FDC) of two,
three (or) four drugs is a preferred dosage form for better patient compliance, efficient
reduction in  viable bacterial  population and minimizing development  of  resistance to
anti-tubercular drugs.
Epidemiology of TB
In  1882 Robert  Koch made the land mark discovery that  TB is caused by an
infectious  agent  Mycobacterium tuberculosis.  Although  demystifying,  Koch’s  finding
introduced the possibility that anti-microbial agent could be developed to combat this
age-old scourge12. Today despite the availability of effective anti-tuberculosis therapy for
50 years. TB remains a major health problem. As the rates of TB infection have fallen
dramatically in industrialized countries in the past century, resource poor countries now
bear over 90% of all cases globally. In fact, there are more cases of TB today than ever
recorded.
Global incidence and prevalence
The WHO estimates that approximately one third of global community is infected
with TB13. In 2000 an estimated 2-9 million incident cases and approximately 3 million
deaths  are  occurred  worldwide  due  to  TB.  After  the  immune  deficiency  virus
(HIV)/AIDS, TB is the second most common cause of death due an infectious disease,
and current trends suggest that TB will still be among 10 leading causes of global disease
burden in the year of 202014.
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The global  distribution of TB cases is skewed heavily toward low-income and
emerging economies. The highest  prevalence of cases is  in Asia,  where China,  India,
Bangladesh, Indonesia, and Pakistan collectively make up over 50% of the global burden.
Africa, have the highest incidence rate of TB, with approximately 83 and 290 per 10000,
respectively. TB cases occur predominantly (approximately 6million of the 8 million) in
the economically most productive 15-49 year old age group  15our understanding of TB
epidemiology  and  the  efficacy  of  control  activities  have  been  complicated  by  the
emergency of drug-resistant bacilli and by the synergism of TB with HIV infection.
Off  the  33.2  million  persons  infected  with  Human  Immuno  Deficiency  virus
(HIV) one third are estimated to also be infected with  Mycobacterium tuberculosis. In
2008, there were an estimated 1.4 million new cases of TB among persons with HIV
infection, and TB accounted for 26%of AIDS related deaths.16
The WHO starts a control programme, for effective control of TB, it reaches 70%
case detection and 85% cure would reduce the incidence rate by 11% per year and the
death  rate  12%per  year  without  the  greater  effort  to  control  tuberculosis,  the  annual
incidence of the disease is expected to increase by 41% between 1998 and 2020.
TB remains a prominent one in international statistics of ill health mainly because
it  kills  young  ones.  More  than  80% of  the  burden  of  TB,  as  measured  in  terms  of
disability adjusted life years lost, is due to premature death rather than illness. About 1.7
million people died of TB in 2004, including 264000 patients who are co-infected with
HIV.17
Effective  control  of  TB  requires  an  understanding  the  epidemiology  of  the
disease.  The  success  in  reducing  the  TB  burden  reflects  several  factors,  including
improved  public  health  efforts,  physician  and  patient  education,  infection  control
measures, and the use of directly observed therapy (DOT). Future efforts to control the
TB will require vigilant public health efforts, improving education of patients and health
care  personnel  and  assuring  adequate  treatment  and  prophylactic  regimens  among
infected individuals.18
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Drugs used to treat TB
TB drugs are classified into two categories, namely first line drugs and second
line drugs. First line drugs are Rifampicin (RIF), Isoniazid (INH), Pyrazinamide (PYZ)
and Ethambutol (ETB) and streptomycin. Second line drugs are Capreomycin, Anamycin,
Ethionamide,  Para  amino  salicylic  acid,  Cyclosporine,  Thiacteazone,  Ciprofloxacin,
Levofloxacin, Ofloxacin, and Saprofloxacin.19
TB drugs in development.
Gatifloxacin
Gatifloxacin  is  a  fluroquinolone;  it  blocks  the  bacterial  DNA gyrase,  thereby
preventing chromosomal  replication.  Gatifloxacin is  currently undergoing  phase  three
clinical trials20.
OPC-67683
POC67683 is a nitromidazo-oxazole, it  inhibits  the cell wall synthesis. Otsuka
Pharmaceuticals (Japan) are conducting the phase two clinical trails. It is effective against
MDR-TB and has no cross resistance with first line TB therapy.21
Moxifloxacin
Mechanism  of  action  of  Moxifloxacin  is  a  broad  spectrum  8-  methoxy,
fluroquinolone with activity against both gram positive and gram negative bacteria.  It
inhibits bacterial DNA gyrase as an enzyme that is essential for the maintaience of DNA
super coils, which is necessary for chromosomal replication. It is undergoing on phase
two and phase three clinical trails.22
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Pyrroles LL3858
Pyrrole LL3858 has potency against drug sensitive TB strains. Phase one clinical
trials are conducting by Lupin Limited (India).23
PA-824
PA-824t  is  a  nitroimidazo-oxazole.  It  inhibits  the  protein  synthesis  and  lipid
synthesis also,  currently it  is  under  phase one clinical  trials,  It  is  more efficient  than
Isoniazid and lesser efficient than the Rifampicin.24
Rifampicin and its bioavailability
The problem with rifampicin is its poor bioavailability poor bioavailability from
Fixed Dose Combinations. Especially in the presence of Isoniazid the decomposition of
rifampicin  is  increases  under  acidic  conditions25.  The  bioavailability  of  rifampicin
reduces when it  is  co-administered with  anta acids  like aluminum hydroxide,  sodium
bicarbonate.26
Rifampicin is readily absorbed from the gastrointestinal tract. Nitti et al showed
that the pharmacokinetic parameters after intravenous infusion do not differ significantly
from those after oral administration of the same doses. Loss et al reported an absolute BA
(bioavailability)  of 93% after a single oral  and intravenous dose of Rifampicin at  the
beginning of the treatment of six adult patients, decreasing to under70% after repeated
dosage due to self induction of metabolizing enzymes by Rifampicin. Rifampicin was
reported to show dose dependent absorption, probably due to saturation of efflux systems
in the small intestine. Analysis of the absolute BA of Rifampicin in a pediatric revealed
that the BA of a freshly prepared oral suspension containing 324 mg/m2 Rifampicin was
only about 50 Rifampicin was only about 50 ±22% of an intravenous dose of 287mg/m2.
Malabsorption of Rifampicin was reported to be common in undernourished patients and
patients with AIDS. The Cmax  after oral administration of 600mg of Rifampicin averages
from about 8-20µg/ml. Cmax values in health volunteers, patients with TB and in children
can vary widely from individual to individual. A plasma protein binding of 80-91% has
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been reported. Most of the unbound fraction is not ionized and diffuses freely in to most
tissues. The main metabolic pathway is deacetylation in the liver and the metabolite is
excreted via biliary pathway but also renally. With in 24 hours about 3-30% of single oral
dose  is  recovered  in  the  feces.  The  antibiotics  shows  dose  dependent  elimination
kinetics.27
Degradation of rifampicin
Degradation studies were performed in 0.1N HCL at 370C in  (USP dissolution
apparatus)  in absence (or) presence of INH. Both RIF and INH were analyzed. The
degradation of RIF was increased approximately three fold in the presence of INH. INH
itself was degraded to lesser extent.28, 29
Rifampicin  is  well  absorbed  from  the  stomach  at  pH  1.2  due  its  solubility.
Isoniazid  is  poorly  absorbed  from  the  stomach,  but  it  is  well  absorbed  from  the
intestine30.  Degradation  of  rifampicin  is  increases  when  it  is  co-administered  with
isoniazid, but isoniazid disappearance was not influenced by rifampicin.
Methods to prevent the degradation of Rifampicin
Rifampicin is degrades rapidly in plasma at ambient temperature, and 54% loss
was  observed  within  8hrs.  This  degradation  is  effectively  decreases  by  adding  the
ascorbic acid. Rifampicin oxidizes in to solution form rifampicin quinine. Ascorbic acid
is  added  to  that  solutions  forms  of  Rifampicin  to  slows  down the  oxidation  and  no
degradation was observed in thawed samples up to 9hrs. 1
Contact between the Rifampicin and Isoniazid can decrease the degradation of the
Rifampicin.  Delay of  the  Rifampicin  release  in  the  acidic  medium was  achieved  by
preparing the  Rifampicin-Sodium Laurly  Sulphate  mixture  in  the  ratio  of  1;1  by co-
grinding method which is a relatively simple and effective method. Thus this approach is
beneficial for the segregation of release pattern of Rifampicin in alkaline environment
and Isoniazid in the acidic environment of the GI tract, which will lead to decrease the
degradation of Rifampicin alone and in combination with Isoniazid.30
9
Back ground of the study
The literature review indicates that  only few approaches including nanoparticles have
been attempted to prevent (or) minimize the degradation of rifampicin with improved
bioavailability.  Ascorbic  acid,  an  antioxidant  has  been  reported  for  preventing
degradation of rifampicin in the plasma sample. Additionally, rifampicin administration
(1000mg/day)  is  also  recommended  in  patients  infected  with  tuberculosis.  To  our
knowledge,  no  study  is  available  on  the  effect  of  ascorbic  acid  on  the  stability  of
rifampicin in animal  model.  Therefore,  the present  study attempted to  investigate the
same.
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4. RIFAMPICIN
Rifampicin
It  is  a  semi-synthetic  derivative  of  Rifamycin  B  isolated  from  Streptomyces
mediterranei.
Structure:
Empirical formula:
C4H58N4O12.
Chemical name:
3-[[  (4-methyi  1-piperazinyl)imino]methyl]-5,6,9,17,19,21-Hexahydroxy-23-
methoxy-2,4,12,16,18,20,22-heptemethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-
2,7-(epoxypentadeca[1,11,.13]trienimino)naphtho[2,1-b]furan-1,11-(2H)-dione21
acetate[13292-46-1].
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Physico- chemical properties.
Colour:
Red-  orange.
Melting point:
138- 188.
Odour:
Odourless.
Solubility:
Slightly soluble in water, Soluble in dilute acidic solutions.
Molecular weight:
822.94.
Mechanism of action31
Rifampicin inhibits the bacteria RNA  polymerase, the enzyme is responsible for
DNA transcription, by forming a stable drug enzyme complex with a binding constant of
10-9M at 370C. The corresponding mammalian enzymes are not infected by Rifampicin.
Bacterial  resistance  to  Rifampicin  is  caused  by mutation  leading  to  a  change  in  the
structure of the β sub unit of RNA polymerase. Such resistance is not an all-or- nothing
phenomenon  rather,  a  large  number  of  RNA  polymerase  with  various  degrees  of
sensitivity to Rifampicin have been found. No strict co-relation exists between enzyme
sensitivity and MIC values, since inhibition of RNA synthesis does not always show up
to the same extent in the two different test systems used for the determination of these
values.
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Formulations of Rifampicin in the market:
Rifampicin capsules 150 mg, 300 mg, 450 mg, 600 mg.
Routes of entry:
Oral:
This is the most frequent route of administration.
Dermal:
Not applicable.
Inhalation:
Not applicable.
Parental:
Rifampicin may be given intravenously.
Eye:
Used to treat ocular Chlamydia infection.
Pharmacokinetics
Absorption
Rifampicin is well absorbed from the gastrointestinal tract. After a dose of 600mg
orally given at least half an hour before breakfast, the peak plasma level is achieved with
in 2-3 hrs. Food interferes the absorption of the Rifampicin.
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Distribution
It is widely distributed throughout the body. Almost 85% of the drug gets bound
to serum proteins. It crosses the placenta, when the meninges are inflamed; the rifampicin
enters in to the cerebrospinal fluid. It  is lipid soluble. The effective concentrations are
present in the lungs, pleural fluid, bile, liver, and urine .It is also distributed in to breast
milk, The apparent volume of distribution is 0.93-0.6L/kg.
Metabolism
The main metabolic pathway is deacetylation in the liver. The API itself and its
deacetylated metabolite  are  mainly excreted  via the biliary pathway but  also renally.
Rifampicin undergoes enterohepatic circulation but its metabolite does not.
Elimination by route of exposure
Rifampicin metabolite is excreted in the bile and also in the urine. Approximately
50% of the dose is  eliminated with in 24hrs and 6-30% of the dose is  eliminated in
unchanged form in the urine, 15% is eliminated as active metabolite. Approximately 43-
60% of oral dose is eliminated in the feces.27
Interactions7
1.  If  Rifampicin  is  co-administered  with  antacids  containing  aluminum hydroxide,  it
reduces the bioavailability of Rifampicin.
2. The Para amino salicylic acid granules and placebo granules significantly decreased
the absorption of Rifampicin.
3. When Rifampicin is co-administered with oral contraceptive pills, it may cause some
menstrual disorders.
4. Rifampicin can decrease the Vitamin D absorption because of induction of enzyme
activity.
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5.  Food lowers  the  peak  blood  levels  because  of  its  interference  with  absorption  of
Rifampicin.
6.  The  drug  induces  hepatic  microsomal  enzymes  and  thus  could  cause  increased
metabolism of several drugs like Hydrocortisone, Verapamil, Phenytoin, Theophylline.
7. Rifampicin and Isoniazid interaction leads to hepatotoxicity.
8. Alcohol intake with Rifampicin increases the risk of hepatotoxicity.
Adverse effects
1. Skin rashes.
2. Diarrhea.
3. Ataxia.
4. Dizziness.
5. Hepatitis.
6. Leucopenia.7
Toxicity7
1. Renal failure.
2. Hemolysis.
3. Thrombocytopenia.
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ISONIAZID
Isoniazid is a synthetic derivative of nicotinic acid with anti-mycobacterial properties,
this is active against actively growing myco-bacteria because it is a pro-drug.
Structure:
Chemical name:
Nicotinic acid hydrazide.
Molecular formula:
C6H7N3O.
Molecular weight:
137.14.
Physical and chemical properties
Colour:
White crystalline powder.
Solubility:
Soluble in water, slightly soluble in chloroform.
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Melting point:
170-1730C.
Mechanism of action
Isoniazid is a pro drug. It is activated by the mycobacterial catalase- peroxidase to
an  active  compound  which  inhibits  the  synthesis  of  mycolic  acid,  an  important
constituent of the mycobacterial cell wall. In addition, the drug inhibits the same catalase-
peroxidase and makes the organism susceptible to oxidative mechanisms.
Formulations of Isoniazid in the market:
Isoniazid tablet 100mg, and 300mg.
Routes of entry:
Oral:
This  is  the  most  frequent  route  of  intoxication  because  the  drug  is  usually
administered orally.
Inhalation:
Not applicable.
Dermal:
Not applicable.
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Pharmacokinetics32
Absorption
Isoniazid is  rapidly and almost  completely absorbed  from the  gastro-intestinal
tract. Peak plasma concentrations are reached within 1-2 hrs after oral administration.
Distribution
Isoniazid is distributed in to all body tissues and fluids. It penetrates well into the
saliva, milk, pleural fluids; It can cross the placental barrier freely.
Biological half-life by route of exposure
The plasma half life in patients with normal renal and hepatic function is 1-4hrs.
Metabolism
The  major  route  of  Isoniazid  metabolism  is  hepatic  acetylation  by  N-acetyl
transferase  which  produces  acetyl  isoniazid.  The  rate  of  acetylation  is  genetically
determined.  Acetyl  Isoniazid  is  further  hydrolyzed  to  isonicotinic  acid  and  acetyl
hydrazine both of which are excreted in urine.
Elimination of route of exposure
Approximately 75-95% of orally administered INH is excreted in urine within
first 24hrs, mainly acetyl isoniazid and isonicotinic acid. In addition, small quantities are
excreted after conjugation with glycine and as isonicotonyl hydrazone.
Interactions
1.  Amino  salicylic  acid,  Procainamide,  Propranolol  increase  INH  serum  levels  by
reduction of the acetylation.
2. Aluminum containing anta acids decrease the gastrointestinal absorption of INH.
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3. Pyrazinamide decreases the serum levels of INH.
4. Food decreases the absorption of INH.
5. Drugs which decreases the serum levels when they are used with INH.
Cyclosporine, Folic acid, ketoconazole, and Verapamil.
6. Drugs which increases the serum levels when they are used with INH
Phenytoin, Diazepam.
Adverse effects
1. Nausea.
2. Loss of appetite.
3. Dark urine.
4. Abdominal pain.
5. Allergy.
6. Liver damage.
7.  Dryness of the mouth.
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ASCORBIC ACID
Ascorbic acid
Ascorbic acid is a form of Vitamin C. Ascorbic acid supplements are vital to the health
and well being of individuals. It  is not naturally produced in the body , It  is found in
citrus fruits like oranges, grapes, and lemons.
Structure:
Chemical name:
L-ascorbic acid.
Empirical formula:
C6H8O6.
Molecular weight:
176.1.
Melting point:
1900C.
Colour:
White to slightly yellowish colour.
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Taste:
Slightly acidic.
Solubility:
Freely soluble in water, sparingly soluble in alcohol, insoluble in chloroform.
Mechanism of action
Ascorbic  acid  has  potent  anti-oxidant  properties,  meaning  is  able  to  reduce
damage caused by oxidizing chemicals, such as free radicals. These oxidizing chemicals
called as reactive species (ROS), are the normal by products of the cellular reactions
takes place in our body. Oxidizing agents are very un stable and damage our cells by
reacting  with  important  molecules  and  changing  how  they  function.  Ascorbic  acid
reduces this damage by directly binding to oxidizing chemicals and converting them to
less harmful molecules. Reducing oxidative damage have many benefits for our body,
including reducing cancer, and heart diseases.
Dosage and administration33
Ascorbic acid is usually administered orally. When the oral administration is not feasible,
the  drug may be  administered  intra-muscular,  and intra-venous.  When it  is  given  by
parental route, the utilization of Ascorbic acid is more. The average protective dose of
this one is for adults are 70-510mg daily. In the presence of scurvy, doses of 300mg-1gm
daily recommended.
Functions
1. Facilitates the growth and repair of the tissue.
2. It  participates in the formation of collagen which is an important connective tissue
protein in skin, bones, teeth, and blood vessels.
3. Improves the iron and calcium absorption.
4. Participates in the transformation of cholesterol in to bile salts.
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5. Prevents the antihistamine activity.
6. Helps in healing of wounds, fractures, and hamorrhages.34
7. Ascorbic acid is a powerful anti-oxidant that can protect our body from the effects of
free radicals.
8. Additionally it reduces the susceptibility of infections.
9. Helps in strengthening our immune system.
Uses
1. It has been used as a means of either curing (or) preventing the common cold.
2. It is used to treat tyrosinemia disease.
3. Used to treat the infections like bladder and prostate.
4. Used for hardening of the arteries.
5. Used for preventing the cataracts.
6. Used in adjuvant cancer.35
7. Treating lead, mercury poisoning.
8. Reducing leg cramps during pregnancy.
9 .In iron deficiency anemia.36, 37
10. Treating loose teeth.38
Toxicity
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1.  Gastrointestinal disturbances like stomach cramps, nausea, and may increase the risk
of developing the stones in kidneys.39
2. Destruction of red blood cells.40
3. Fluctuations in the blood pressure.
4. Irregular breathing.
5. Excessive chewing of ascorbic acid (Vitamin C) may leads to jaundice.
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OBJECTIVE
5. AIM AND OBJECTIVE
To investigate the effect of ascorbic acid on the stability and pharmacokinetics of
rifampicin alone and in combination with Isoniazid in rabbits. The following objectives
were examined.
In-vitro dissolution stability studies on;
a) Rifampicin (300mg).
b) Rifampicin (300mg) +Isoniazid (150mg)
c) Rifampicin (300mg) +Isoniazid (150mg) +Ascorbic acid (125mg).
d) Rifampicin (300mg) +Isoniazid (150mg) +Ascorbic acid (250mg).
e) Rifampicin (300mg) +Isoniazid (150mg) +Ascorbic acid (500mg).
f) Rifampicin (300mg) +Ascorbic acid (125mg).
g) Rifampicin (300mg) +Ascorbic acid (250mg).
h) Rifampicin (300mg) +Ascorbic acid (500mg).
In-vivo pharmacokinetic study:
1. Rifampicin. (21.4mg/kg).
2.  Rifampicin (21.4mg/kg) +Isoniazid (10.7mg/kg).
3.  Rifampicin  (21.4mg/kg)  +Isoniazid  (10.7mg/kg)  +Ascorbic  acid  (35.7mg/kg)(Best
formulation of in-vitro).
4. Rifampicin (21.4mg/kg) +Ascorbic acid (35.7mg/kg) (Best formulation of in-vitro).
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6. PLAN OF WORK
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PLAN OF WORK
In-vitro dissolution study In-vivo pharmacokinetic
study
Rifampicin (300mg)
Rifampicin (300mg) +
Isoniazide (150mg)
Rifampicin (300mg) +
Isoniazide (150mg) +
Ascorbic acid (125mg)
Rifampicin (300mg) + 
Isoniazide (150mg) + 
Ascorbic acid (250mg)
Rifampicin (300mg) +
Isoniazide (150mg) +
Ascorbic acid (500mg)
Rifampicin (300mg) +
Ascorbic acid (125mg)
Rifampicin (300mg) +
Ascorbic acid (250mg)
Rifampicin (300mg) +
Ascorbic acid (500mg)
Rifampicin (21.4 mg/kg)
Rifampicin + Isoniazide
(10.7mg/kg)
Rifampicin + Isoniazide
+ Ascorbic acid
(35.7mg/kg)
Rifampicin +
Ascorbic acid (35.7
mg/kg)

7. METHOLODGY
In-vitro dissolution stability study
Drugs:
Rifampicin  pure  a  gift  sample  and  isoniazid  was  obtained  from  Astha
Laboratories Pvt.  Ltd,  Hyderabad, Andhra Pradesh, India.  Ascorbic acid was obtained
from Qualigens Fine Chemicals, Mumbai.
Chemicals:
KCl from Loba Cheme Pvt Ltd, Mumbai.
HCl from Loba Cheme Pvt Ltd, Mumbai.
Preparation of pH 1.2
 50ml 0f 0.2M KCl was mixed with 85ml of 0.2M HCl and make up to 900ml with water.
In-vitro dissolution stability study of RIF in pH 1.2 solution
Dissolution profile of pure rifampicin(300mg), rifampicin(300mg) +isoniazid
(150mg) rifampicin (300mg)+isoniazid(150mg) +ascorbic acid in varying concentrations
(125mg, 250mg 500mg)and rifampicin +ascorbic acid in varying concentrations (125mg,
250mg 500mg) were evaluated according to the method described in USFAD. Preparer
900ml (0.1N HCL) of the dissolution medium of pH 1.2 buffer and pour it in to the vessel
and temperature of medium was maintained at 37±0.2°C . The sample was placed in the
medium and the dissolution was performed at 100rpm. 10ml of samples were withdrawn
at 0, 15, 30, 45, and 60 min  and equivalent amount of dissolution medium were added to
maintain sink conditions . The obtained samples analyzed by UV spectrophotometer at
475nm. The experiment were carried out in triplicate and mean values and SD were
recorded and the percentage degradation was calculated by using the given formula.2
% Degradation loss was calculated by using formula
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Initial concentration – Final concentration
                                                                          X100
Initial concentration
In-vivo pharmacokinetic study
Animals:
A white New Zealand rabbits weighing 1.5 to 2.5kg were obtained from Swamy
Vivekananda College of pharmacy  animal house .The animals were feed with cabbage
and water. They were maintained in standard laboratory conditions 21±2 0C and relative
humidity of 55-60%. The animals were overnight fasted before the experiment. The study
protocol was approved by the Institutional Animal Ethical Committee and the protocol
number is SVCP/IAEC/M.Pharm/03/2011.
Drugs:
Rifampicin  and  Isoniazid  were  obtained  from  Astha  Laboratories  Pvt.  Ltd,
Hyderabad,  Andhra  Pradesh,  India.  Ascorbic  acid  was  obtained  from Qualigens  Fine
Chemicals, Mumbai.
Chemicals:
1% CMC from Loba Cheme Pvt Ltd, Mumbai.
95% v/v alcohol.
Requirements:
Cotton.
Surgical blade.
26G  needle.
Blood collecting tubes (EDTA tubes).
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Plasma sample collecting tubes.
Sex:
Both Male/Female.
No. of animals:
12.
Animal dose:
Rifampicin:
21.4mg/kg p.o.
Isoniazid:
10.7mg/kg p.o.
Ascorbic acid:
35.7mg/kg p.o.
Procedure for collection of blood:
The rabbit  was placed in a restrainer.  The hair present on the ear  was shaved
smoothly with blade without disturbing the blood vessels. Ear was cleaned with 95% v/v
alcohol on the collection site and rapid rubbing on the ear to  dilate blood vessels which
is easily to collect the blood. 2G needle was inserted in to the marginal ear vein to collect
the blood from marginal ear vein. After collecting the blood, clean sterile cotton was kept
on the collection site and finger pressure was applied to stop the bleeding.42
Experimental  procedure: Rabbits  were classified into 4 different  groups each group
consisting of 3 animals.
Group1: Control (Rifampicin alone).
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Group 2: Rifampicin + Isoniazid.
Group3: Rifampicin+ Isoniazid+ Ascorbic acid.
Group4: Rifampicin+ Ascorbic acid.
Preparation of samples:
The samples were suspended in water using 1%CMC as a suspending agent and
used for this study.
Each group of animals (three rabbits) was administered the samples as shown as
above through an intra gastric tube after a overnight fasting. Blood samples (1 ml) were
collected in to heparinized tubes from the marginal ear vein at 0, 0.5, 1, 2, 4, 6, 9 and 12 h
after drug administration and plasma was separated by using centrifugation and stored at
-20°C. Samples were by analyzed by high performance liquid chromatography (HPLC).43
BIOANALYTICAL WORK
Extraction of rifampicin from plasma:
The mobile phase consisted of acetonitrile 0.05 M sodium citrate buffer adjusted
to pH 4.0 with 0.05 M hydrochloric acid (42:58) and pumped at a flow-rate of 2.3 ml/min
a ant ambient temperature. Buffer was filtered through an Whatman filter paper. Mobile
phase was filtered (cellulose acetate filter diameter 47 mm, pore size 0.45 µm, Sartorius
AG. 370700) and sonicated (EYELA-Sonicator) for 12 min.44
An aliquot of 200 µl of plasma samples was pipette into an eppendrof’s tube of
1.5ml  capacity.  Acetonitrile  (300  µl)  was  added,  vortexes  for  one  minute  and  micro
centrifuged at 10,000 rpm for 5min. then 300 µl of the supernatant was taken into another
micro centrifuge tube and vacuum dried in the HETO vacuum centrifuge. The residue
obtained was reconstituted in 100 µl of mobile phase.  Plasma was filtered through 0.22
µm membrane (13 mm) and 20 µl volumes was injected.45
HPLC analyses
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Rifampicin  was  analyzed  at  ambient  temperature  on  a  Kromasil  C18 column
Phenomenex, UK, 100mm×3.2mm i.d.,  3µm particle  size) with an ODS Securigard®
guard  column  4mm×3mm  (Phenomenex,  Macclesfield,  UK).  The  mobile  phase
ammonium acetate buffer adjusted to pH 4.0 with glacial acetic acid and acetonitrile was
delivered at 0.7ml/min on a gradient program (20-90% acetonitrile over 18 min) by a
spectra system P2000 pump. The analytes were detected by a UV detector at 334nm. The
injection volume for each sample was 20µl to column.1The peak was found at 2.52 min,
which was probably the 25-desacetylrifampicin metabolite. HPLC analyses showed that
the assay method is linear in the ranges 0.1-1µg/ml for plasma. The chromatograms were
recorded according to the “Area normalization method” with the measurement of peak
area.46
Extraction efficiency
The extraction efficiency was calculated by comparing the peak heights of rifampicin
spiked-pooled blank plasma samples with that of respective standard rifampicin samples.
Calibration curve for rifampicin
A calibration curve of rifampicin was obtained by plotting the concentration of
rifampicin  against  the  respective  spiked-pooled  blank  plasma  samples  peak  area.
Concentration of rifampicin was calculated by using the following equation.
Y = MX+ C
Pharmacokinetic parameters47, 48
The pharmacokinetic parameters were calculated for each rabbit of group I,  group II,
group III and group IV, by the semi logarithmic plot of plasma rifampicin concentration
at various intervals. The following pharmacokinetic parameters were calculated:
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1. Elimination rate constant (Ke): The elimination rate constant was calculated by using
the formula.
Ke = -2.303 x slope of extrapolated curve.
2. Elimination half life (t1/2): t1/2 was calculated by the following using the formula.
t1/2 = 0.693/Ke
3. Absorption rate constant (Ka):  This was calculated by the method of residuals. The
log linear portion of the decline phase was back extrapolated for each curve. The plasma
concentration along this extrapolated line was C. the observed plasma concentration C
was subtracted from the corresponding extrapolated value at each time point. The semi
logarithmic plot of residuals (C-C) against time yields a straight line.
Ka = -2.303 x slope of residual line
4. Absorption half life: It was calculated using the formula.
5. T1/2(a) apparent volume of distribution (Vd): It was calculated by using the following
formula.
Vd =             Ka F X0
                (Ka - Ke) y intercept
6. Tmax was calculated using the formula.
tmax =        ln Ka - ln Ke
                                                    Ka-Ke
7. Maximum plasma concentration (Cmax): Cmax was calculated using the formula.
Cmax =    Y intercept (e-Ke. Tmax – e-Ka. Tmax)
8. Area under curve (AUC0-12): AUC0-12 was calculated using the formula.
AUC   =       F X0
                             Vd. Ke
9. AUC0-∞ was calculated using the formula.
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AUC0-∞ =     C0
                                         Ke
Statistically analysis:
The data were analyzed.  One way ANOVA followed by Tukey’s multiple comparison
Test with the help of Graph Pad Instat software, version 3.01. (P<0.05 )considered as
significant.
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DISCUSSION
8. RESULTS AND DISCUSSION
IN-VITRO STABILITY STUDY:
Table1.
Calibration curve of pure Rifampicin in pH1.2
Concentration Absorbance
0 0
2 0.18
4 0.41
6 0.62
8 0.84
10 1
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R² = 1
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Figure- 1
Table2.
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 Calibration curve of Isoniazid at pH1.2
Figure-2
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Concentration Absorbance
0 0
2 0.21
4 0.43
6 0.64
8 0.85
10 0.97
Table3.
Calibration curve of Rifampicin +Isoniazid +Ascorbic acid (125mg)
Concentration Absorbance
0 0
2 0.17
4 0.37
6 0.56
8 0.74
10 0.9
0 2 4 6 8 10 12
0
0.2
0.4
0.6
0.8
1
f(x) = 0.09x - 0
R² = 1
Standard curve of RIF+INH+ASC 125MG at Ph 1.2
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A
b
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a
n
ce
Figure-3
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Table4.
Calibration curve of Rifampicin +Isoniazid +Ascorbic acid (250mg)
Concentration Absorbance
0 0
2 0.2
4 0.43
6 0.63
8 0.84
10 0.99
0 2 4 6 8 10 12
0
0.2
0.4
0.6
0.8
1
1.2
f(x) = 0.1x + 0.01
R² = 1
Syandard curve of RIF+INH+ASC 250mg at Ph 1.2
Concentration
A
b
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a
n
ce
Figure-4
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Table5.
Calibration curve of Rifampicin +Isoniazid +Ascorbic acid (500mg)
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R² = 1
Standard curve of RIF+INH+ASC 500mg at Ph 1.2
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Figure-5
37
Concentration(µg) Absorbance
0 0
2 0.2
4 0.41
6 0.62
8 0.78
10 0.95
Table6.
Calibration curve of Rifampicin +Ascorbic acid (125mg)
0 2 4 6 8 10 12
0
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1
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f(x) = 0.1x + 0.01
R² = 1
Standard curve of RIF+ASC 125mg at pH 1.2
Concentration
A
b
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rb
a
n
ce
Figure-6
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Concentration(µg) Absorbance
0 0
2 0.21
4 0.42
6 0.64
8 0.86
10 0.99
Table7.
Calibration curve of Rifampicin +Isoniazid (250mg)
Concentration (µg) Absorbance
0 0
2 0.23
4 0.4
6 0.59
8 0.74
10 0.92
0 2 4 6 8 10 12
0
0.2
0.4
0.6
0.8
1
f(x) = 0.09x + 0.03
R² = 1
Standard curve of RIF+ASC 250mg at Ph1.2
Concentration
A
so
rb
a
n
ce
b
                
Figure-7
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Table 8.
Calibration curve of Rifampicin +Ascorbic acid (500mg)
0 2 4 6 8 10 12
0
0.2
0.4
0.6
0.8
1
1.2
f(x) = 0.1x + 0.01
R² = 1
Standard curve of RIF+ASC 500 mg at Ph1.2
Concentration
A
b
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a
n
ce
Figure-8
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Concentration(µg) Absorbance
0 0
2 0.21
4 0.41
6 0.61
8 0.82
10 0.98
TABLE9.
 PERCENTAGE DRUG RELEASE OF RIFAMPICIN ALONE AT PH 1.2
Time(min) Trial 1 Trial2 Trial3 Cumulative
%drug release
0 0 0 0 0
15 30 32.3 35.1 32.4±2.554
30 41 42.5 40.1 41.2±1.212
45 48 47.6 45.1 46.9±1.572
60 56 56.4 59.4 57.2±1.858
**P<0.01
Table10.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 14 13.9 14.3 14±0.2082
30 18 18.5 19 18.5±0.5
45 21 22 20.5 21.1±0.7638
60 26 25.3 26.7 26±0.7
**P<0.01
Table11.
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PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID AND ASCORBIC ACID (125MG) AT PH 1.2
Time(min) Trial1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 40 41.9 42.7 41.5±1.387
30 51 51.7 50 50.9±0.8544
45 59 59.6 60 59.5±0.5033
60 64 63.7 64.8 64.1±0.5686
***P<0.001
Table12.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID AND ASCORBIC ACID (250MG) AT PH 1.2
Time(min) Trial 1 Trial2 Trial3 Cumulative
%drug release
0 0 0 0 0
15 44 44.3 43.7 44±0.3
30 56 56.7 55.8 56.1±0.4726
45 60 61.1 62 61±1.002
60 69 70 71.3 70.1±1.153
***P<0.001
Table13.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID AND ASCORBIC ACID (500MG) AT PH 1.2
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Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 50 50.7 51 50.5±0.5132
30 59 59.3 60 59.4±0.5131
45 63 63.1 62.7 62.9±0.2082
60 74 74.3 75 74.4±0.513
***P<0.001
Table14.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ASCORBIC ACID (125MG) AT PH 1.2
Time(min) Trial 1 Trial2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 45 45.3 44.7 45±0.3
30 56 56.2 57 56.4±0.5292
45 61 61.7 60.8 61.1±0.4726
60 68 67.3 68.2 67.8±0.4726
***P<0.001
Table15.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ASCORBIC ACID (250MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 48 48.3 47.7 48±0.3
30 60 61.2 60.3 60.5±0.6245
43
45 64 65 65.4 64.8±0.7211
60 75 75.3 76 75.4±0.5132
***P<0.001
Table16.
PERCENTAGE DRUG RELEASE OF RIFAMPICIN IN THE PRESENCE OF
ASCORBIC ACID (500MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 55 54.9 55.3 55±0.2082
30 64 64.6 63.9 64.1±0.3786
45 68 68.2 69 68.4±0.5292
60 79 78.8 81.2 79.6±1.332
***P<0.001
COMPARATIVE PERCENTAGE DRUG RELEASE OF 
RIFAMPICIN AT PH1.2
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Table17.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN ALONE AT PH 1.2
45
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 70 67.7 64.9 67.5±2.554
30 59 57.5 59.9 58.8±1.212
45 52 52.4 54.9 53.1±1.572
60 44 43.6 40.6 42.7±1.858
***P<0.001
Table18.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF ISONIAZID AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 86 86.1 85.7 85.9±0.2082
30 82 81.5 81 81.5±0.5
45 79 78 79.5 78.8±0.7638
60 74 74.7 73.3 74±0.7
**P<0.01
Table19.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF   ISONIAZID AND ASCORBIC ACID (125MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 60 58.1 57.3 58.4±1.387
30 49 48.3 50 49.1±0.8544
46
45 41 40.4 40 40.4±0.5033
60 36 36.3 35.2 35.8±0.5686
***P<0.001
Table20.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF   ISONIAZID AND ASCORBIC ACID (250MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 56 55.7 56.3 56±0.3
30 44 43.3 44.2 43.8±0.4726
45 40 38.9 38 38.9±1.0
60 29 30 28.7 29.2±0.6807
***P<0.001
Table21.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF ISONIAZID AND ASCORBIC ACID (500MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 50 49.3 49 49.4±0.5132
30 41 40.7 40 40.5±0.513
45 37 36.9 37.3 37±0.2082
60 26 25.7 25 25.5±0.5132
***P<0.001
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Table22.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF ASCORBIC ACID (125MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 55 54.7 55.3 55±0.3
30 44 43.8 43.8 43.8±0.1528
45 39 38.3 39.2 38.8±0.4726
60 32 32.7 31.8 32.1±0.472
***P<0.001
Table23.
PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF ASCORBIC ACID (250MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 52 51.7 52.3 52±0.3
30 40 38.8 39.7 39.5±0.6245
45 36 35 34.6 35.2±0.7211
60 25 24.7 24 24.5±0.5132
***P<0.001
Table24.
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PERCENTAGE DRUG DEGRADATION OF RIFAMPICIN IN THE PRESENCE
OF ASCORBIC ACID (500MG) AT PH 1.2
Time(min) Trial 1 Trial 2 Trial 3 Cumulative
%drug release
0 0 0 0 0
15 45 45.1 44.7 44.9±0.2082
30 36 35.4 36.1 35.8±0.3786
45 32 31.8 31 31.6±0.5292
60 21 21.2 18.8 20.3±1.332
***P<0.001
COMPARATIVE PERCENTAGE DRUG DEGRADATION OF
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Figure-10
IN-VIVO PHARMACOKINETIC STUDY
HPLC Graphs of Rifampicin alone
Fig- 11
50
Fig-12
Fig-13
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Fig-14
Fig-15
52
Fig-16
HPLC Graphs of Rifampicin+ Isoniazid
     Fig-17
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Fig-18
Fig-19
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Fig-20
Fig-21
HPLC Graphs of Rifampicin +Isoniazid +Ascorbic acid
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PLASMA SAMPLE AT 30 MIN
Fig-22
Fig-23
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Fig-24
Fig-25
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Fig-26
Fig-27
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Fig-28
HPLC Graphs of Rifampicin +Ascorbic acid
Fig-29
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Fig-30
Fig-31
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Fig-32
Fig-33
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Fig-34
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Table25.
 PLASMA CONCENTRATION OF RIFAMPICIN ALONE AT VARIOUS TIME
INTERVALS IN GROUP1 RABBITS
Time(hr)
Animals
Mean± S.E.M
1 2 3
0.5
1
2
4
6
9
12
3.9
5
6.8
5.6
3.7
0.9
-
4
5.2
7.1
6.2
3.5
1
-
3.7
5.4
7.5
5.7
3.2
1.1
-
3.8±0.088
5.2±0.1155
7.1±0.2028
5.8±0.1856
3.4±0.1453
1±0.05774
-
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Table26.
 PLASMA CONCENTRATION OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID AT VARIOUS TIME INTERVALS IN GROUP2 RABBITS
Time(hr)
Animals
Mean± S.E.M
1 2 3
0.5
1
2
4
6
9
12
1.9
4
5.1
3.9
2.9
-
-
2.3
4.2
5.3
4
3
-
-
2.6
4.4
4.9
4.1
2.8
-
-
2.2±0.202
4.2±0.1155
5.1±0.115
4±0.057
2.9±0.054
-
-
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Table27. 
PLASMA CONCENTRATIONS OF RIFAMPICIN IN THE PRESENCE OF
ISONIAZID + ASCORBIC ACID AT VARIOUS AT VARIOUS TIME INTERVALS
IN GROUP3 RABBITS
Time(hr)
Animals
Mean±S.E.M1 2 3
0.5
1
2
4
6
9
12
5.4
6.9
9
8.6
6.7
2.8
1.6
5.8
7.1
9.1
8
6.3
2.3
2.1
6
7.4
9.2
8.8
6.6
2.7
1.9
5.7±0.176
7.1±0.145
9.1±0.057
8.4±0.24
6.5±0.12
2.6±0.152
1.8±0.145
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Table28.
Time(hr)
Animals
Mean±S.E.M1 2 3
0.5
1
2
4
6
9
12
6
8.1
9.7
9.9
8
4.1
2.7
6.2
8.6
10.1
10.2
8.1
4.3
1.9
6.4
8.4
10.3
9.8
7.9
3.9
2.3
6.2±0.115
8.3±0.1453
10±0.1764
9.9±0.01202
8±0.0574
4.1±0.1155
2.3±0.2309
PLASMA CONCENTRATION OF RIFAMPICIN IN THE PRESENCE OF
ASCORBIC ACID AT VARIOUS TIME INTERVALS IN GROUP4 RABBITS
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PHARMACOKINETIC CALCULATIONS
Table29.
S.no Parameters
Animals
Mean±S.E.M
1 2 3
1
2
3
4
5
6
7
8
Kehr-1
Kahr-1
T1/2hr
Vd lit
Tmax hr
Cmax µg/ml
AUC0-12µg/ml ,h
AUC0-∞12µg/ml ,h
0.398
0.419
1.7
0.91
1.2
5.90
34.31
60.61
0.335
0.425
1.85
0.93
1.3
5.82
36.21
62.60
0.358
0.431
1.92
0.95
1.5
6
31.36
59.94
0.363±0.0184
0.425±0.0034
1.823±0.064
0.93±0.011
1.333±0.088
5.906±0.052
33.96±1.411
61.05±0.798
PHARMACOKINETICS OF RIFAMPICIN ALONE IN GROUP 1(N=3).
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Table30.
PHARMACOKINETICS OF RIFAMPICIN + ISONIAZID IN GROUP 2 (N=3)
S.n
o
Parameters
Animals
Mean±S.E.M1 2 3
1
2
3
4
5
6
7
8
Kehr-1
Kahr-1
T1/2hr
Vd lit
Tmax hr
Cmax µg/ml
AUC0-12µg/ml.h
AUC0-∞µg/ml.h
0.295
0.3151
2.7
0.83
1.61
4.10
29.13
50.14
0.299
0.318
2.4
0.87
1.63
4.16
28.16
54.31
0.310
0.321
2.5
0.89
1.68
4
26.15
56.14
0.301±0.004
0.318±0.001
2.533±0.088
0.863±0.017
1.64±0.020
4.086±0.046
27.81±0.877
53.53±1.775
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Table31.
 PHARMACOKINETICS OF RIFAMPICIN +ISONIAZID +ASCORBIC ACID IN
GROUP 3 (N=3)
S.n
o
Parameters
Animals
Mean±S.E.M1 2 3
1
2
3
4
5
6
7
8
Kehr-1
Kahr-1
T1/2hr
Vd lit
Tmax hr
Cmax µg/ml
AUC0-12µg/mlh
AUC0-∞µg/mlh
0.418
0.525
0.99
0.99
1
9.24
64.68
78.90
0.421
0.533
0.97
1
1.1
9.28
68.16
81.77
0.433
0.545
1
1.2
1.3
9.31
74.6
86.7
0.424±0.004
0.534±0.005
1.594±0.008
1.603±0.068
1.133±0.088
9.276±0.020
69.146±2.906
82.48±2.099
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Table32. 
PHARMACOKINETICS OF RIFAMPICIN +ASCORBIC ACID IN GROUP 4
(N=3).
S.n
o
Parameters
Animals
Mean±S.E.M1 2 3
1
2
3
4
5
6
7
8
Kehr-1
Kahr-1
T1/2hr
Vd lit
Tmax hr
Cmax µg/ml
AUC0-12µg/mlh
AUC0-∞µg/mlh
0.615
0.514
0.95
1
1.2
10
70.81
77.90
0.614
0.511
0.97
1.3
1.4
10.2
72.03
86.77
0.616
0.531
0.94
1.5
1.6
10.4
71.42
81.10
0.518±.006
0.615±0.0005
0.953±0.008
1.266±0.145
1.02±0.115
10.2±0.115
71.42±0.352
89.54±2.593
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GRAPHICAL REPRESENTATION OF PHARMACOKNETICS PARAMETERS
Elimination rate contstant
KE
0.0
0.2
0.4
0.6
rifampicin
rifampicin+isoni
rifampicin+isoni+ascbic
rifampi+ascorbic acid
Fig-36
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Absorption rate constant Ka
0.0
0.2
0.4
0.6
0.8
rifampicin
rifam+ iso
rifam+ iso+ascr
rifa+ ascor
Fig-37
HALF LIFE t1/2
0
1
2
3
rifampicin
rifa+ isoniazid
rifampicin+iso+ascacid
rifampicin+ascorbicacid
Fig-38
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Volume of distribution Vd
0.0
0.5
1.0
1.5
rifafmpicin
rifampicin+isoni
rifamipicin+isonia+ascacid
rifampicin+asccorbic acid
                                                            Fig-39
Concentration  Cmax
0
5
10
15
rifampicin
rifamp+isoni
rifampcin+iso+ascr
rifampicin+ascrb
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                                                      Fig-40
Tmax
0.0
0.5
1.0
1.5
2.0
rifampicin
rifampicin+isoniazid
rifampicin+ison+asc
rifam+ascacid
                                                    Fig-41
AUC 0-12 (hr)
0
20
40
60
80
rifampicin
rifampicin+iso
rifacin+iso+ascacid
rifa+ascacid
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                                                     Fig-42
AUC  0-∞
0
20
40
60
80
100
rifampicin
rifampicin+iso
rifampicin+iso+asbicacid
rifampicin+ascorbicacid
                                                       Fig-43
IN-VITRO DISSOLUTION STABILITY STUDY
The results of in-vitro dissolution stability of RIF, RIF+INH, RIF +Ascorbic acid
(varying  concentrations  125mg,250mg,and500mg)  and  RIF+  Ascorbic  acid  (varying
concentrations  125mg,250mg,and500mg)  are  shown  in  tables9-16  and  figure9.  The
stability  of  rifampicin  was  ascertained  from the  % release  of  the  drug  at  60min,  as
rifampicin was absorbed maximal with in an hour from the acidic environment of the
stomach and so the % release of  drug was limited to 60min. The % drug release of
rifampicin in pH1.2 buffer at 60min was57.2% and it was reduced to 26% in the presence
of isoniazid and this reduction was statically significant (***p<0.001).
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  Ascorbic acid in (varying concentrations 125mg, 250mg, and500mg) reverse the
% drug release and the maximum effect was observed (74.4%) with higher concentration
of ascorbic acid (500mg) and this reduction was statically significant (***p<0.001), this
finding indicates that ascorbic acid protects rifampicin degradation by isoniazid and so an
enhanced amount of rifampicin release was observed in the presence of ascorbic acid.
The effect of ascorbic acid on % release of rifampicin alone at 60min was also observed
and it was found the % release of rifampicin increased as the concentration of ascorbic
acid increased and this increase was found to be ascorbic acid concentration dependent.
Maximum % release of rifampicin (79.6%) was observed with higher concentration of
ascorbic acid (500mg). The above findings clearly suggest and improved % release of
rifampicin either alone (or) in the presence of isoniazid by the effect of ascorbic acid. The
results of the dissolution study reveal that absorption of rifampicin even in the presence
of isoniazid can be significantly improved through inhibition of degradation of rifampicin
with more availability of rifampicin for dissolution and absorption.
    From the in-vitro release data the % degradation of rifampicin at 60min was
also determined and the influence of ascorbic acid on stabilizing rifampicin alone (or) in
the presence of isoniazid was ascertained. The results of  % degradation of rifampicin are
shown in tables17-24 and figure10, rifampicin degraded to the extent 42.7 % at pH 1.2
buffer at 60min and the of  % degradation of rifampicin significantly increased to (74 %)
in the presence of isoniazid (***p<0.001). As ascorbic acid (125mg) addition reduce the
degradation of rifampicin from 42.7%-32.1% (***p<0.001) and as the concentration of
ascorbic acid increased the % degradation of rifampicin was proportionately decreased ,
the % reduction of degradation of rifampicin in the presence of ascorbic acid 1254mg,
250mg, and 500mg was 32.1%, 24.5%, and 20.3% respectively and this reduction was
statically significant (***p<0.001).
 Similarly  effects  of  ascorbic  acid  were  observed  on  the  %  degradation  of
rifampicin in the presence of isoniazid, the % degradation of rifampicin in the presence of
isoniazid was 74% and degradation of rifampicin was significantly reduced (***p<0.001)
to 35.8%, 29.2%, and 25.5% with ascorbic acid 125mg, 250mg, and 500mg respectively,
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these  data  signal  the  beneficial  effects  of  ascorbic  acid  addition  to  overcome  (or)
minimize the degradation of rifampicin in the gastric environment.
    In-vivo pharmacokinetic study:
In-vivo pharmacokinetic parameters like Ke, Ka, Tmax, Cmax, Vd, T1/2, AUC0-12, AUC0-
∞ there  also  studied  in  rabbits  in  order  to  ascertain  whether  the  in-vitro  release  and
degradation data of rifampicin would be truly reflected in-vivo bioavailability. The results
of the pharmacokinetic study as shown in tables 25-32 and figures 11-43. 
    Ke,  Ka,   Cmax, AUC0-12,AUC0-∞  of rifampicin were significantly increased by the
effect of ascorbic acid (***p<0.001), these findings clearly suggest that the amount of
rifampicin available for absorption was significantly increased in the presence of ascorbic
acid due the effect of ascorbic acid on protecting the rifampicin against degradation in the
acidic environment and as such Ke, Ka,  Cmax, AUC0-12,AUC0-∞ were significantly increased,
isoniazid significantly reduced  Ke, Ka,  Cmax, AUC0-12,AUC0-∞  of rifampicin (***p<0.001),
indicative  of  the  catalytic  degradation  effect  of  isoniazid  on  rifampicin  which  is
inconsistent  we  early  finding.49,  50,  51,  52,  53 As  ascorbic  acid  reversed  the  above
pharmacokinetic parameters of rifampicin brought about by isoniazid to values greater
than the corresponding values, pure rifampicin and the effect was statically significant
(***p<0.001),  these  finding  again  support  the  contention  that  ascorbic  acid  protects
rifampicin against degradation even in the presence of isoniazid, As Ke,  Ka  of rifampicin
alone (or) in the presence of isoniazid were improved by ascorbic acid, the t1/2,and tmax
were significantly reduced acid (***p<0.001).
    Previously  it  has  been  documented  that  ascorbic  acid  was  used  stabilize
rifampicin in the plasma sample. However to this effect, to the best of our knowledge no
report  is  available on the effect  of  ascorbic acid  on the in-vitro  stability and in-vivo
pharmacokinetics of rifampicin, this is first time we are reporting on the beneficial effects
of ascorbic acid in preventing (or) minimizing rifampicin degradation on improving its
bioavailability.
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   Our findings in the present study propose that  degradation of  rifampicin in
combination with isoniazid (or) through fixed dose combinations of rifampicin, isoniazid,
pyrazinamide, and ethambutol can be controlled by using ascorbic acid in appropriate
concentrations.  It  has  been  documented  that  tuberculosis  patients  should  be  given
ascorbic  acid  1000mg/day  and  therefore  our  study  justifies  the  recommendation  of
ascorbic  acid  addition to  rifampicin formulations  in order  to  control  degradation and
improve  bioavailability  of  rifampicin  for  effective  management  of  tuberculosis.  It
strongly recommended  for  the  clinical  study on  the  viability  of  beneficial  effects  of
improved bioavailability of rifampicin in clinical practice. 
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CONCLUSION
9. SUMMARY AND CONCLUSION
• Rifampicin degrades in pH 1.2 medium.
• The degradation of rifampicin was further influenced by isoniazid.
• Ascorbic acid in varying concentrations (125mg, 250mg and 500mg) can control 
the degradation of rifampicin even in the presence of isoniazid. 
• The stabilization effect of ascorbic acid on rifampicin was reflected in the 
pharmacokinetic parameters.
• Ka. Ke, Cmax, AUC0-12, AUC0-∞ of rifampicin were significantly increased by the 
effect of ascorbic acid.
• T1/2, and Tmax of rifampicin were also significantly reduced by ascorbic acid.
• It can be concluded that ascorbic acid can be included in the formulations 
containing rifampicin for improving its bioavailability.
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